Peruvoside
Appearance
![]() | |
Clinical data | |
---|---|
Other names | (3S,5R,10R,13R,14S,17R)- 3-[(2S,5R)- 3,5-dihydroxy- 4-methoxy- 6-methyloxan- 2-yl]oxy- 14-hydroxy- 13-methyl- 17-(5-oxo-2H-furan-3-yl)- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopenta[a]phenanthrene- 10-carbaldehyde |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.013.327 |
Chemical and physical data | |
Formula | C30H44O9 |
Molar mass | 548.673 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
![]() | This article may be too technical for most readers to understand.(February 2021) |
Peruvoside (or cannogenin thevetoside) is a cardiac glycoside[1] for heart failure.[2]
It is derived from Cascabela thevetia (Thevetia neriifolia).[2]
References
- ^ Arora RB, Rangaswami S (1972). Peruvoside and Other Cardiotonic Glycoside[s] of Thevetia neriifolia Juss: Chemical, Pharmacological, and Clinical Studies. New Delhi, India: Thomson. LCCN 78900408.
- ^ a b Bhatia ML, Manchanda SC, Roy SB (September 1970). "Haemodynamic studies with peruvoside in human congestive heart failure". British Medical Journal. 3 (5725): 740–3. doi:10.1136/bmj.3.5725.740. PMC 1701679. PMID 4919553.